Petrović Dejan, Stojimirović Biljana
Klinicki centar Kragujevac, Kragujevac.
Med Pregl. 2010 Sep-Oct;63(9-10):674-80. doi: 10.2298/mpns1010674p.
INTRODUCTION Cardiovascular disease is a leading cause of death among hemodialysis patients.
Secondary hyperparathyroidism is one of the main factors for the development of cardiovascular complications among these patients. A high concentration of parathormone, hypercalcemia, hyperphosphatemia and high calcium x phosphate product among dialysis patients play a crucial role in the development of vascular (calcification of coronary artery) and valvular calcifications. DISCUSSION AND CONCLUSION With every new patient on hemodialysis it is necessary to see if there is a vascular/valvular calcification in order to single out the patients at risk of progression of coronary artery calcification and to use non-calcium containing binder phosphate in due time. Non-calcium containing binder phosphate, new active vitamin D agents and calcimimetics prevent the development of secondary hyperparathyroidism as well as cardiovascular complications and decrease the rate of cardiovascular morbidity and mortality of these patients.
